Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP

📖 Wiki Page

therapeutic2860 wordssynced 2026-04-02

Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP

Overview

...

Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Class</td>
<td>Precursor</td>
</tr>
<tr>
<td class="label">Resolvins (E-series)</td>
<td>EPA</td>
</tr>
<tr>
<td class="label">Resolvins (D-series)</td>
<td>DHA</td>
</tr>
<tr>
<td class="label">Protectins</td>
<td>DHA</td>
</tr>
<tr>
<td class="label">Maresins</td>
<td>DHA</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">17-HDHA (17-hydroxydocosahexaenoic acid)</td>
<td>100-200 mg</td>
</tr>
<tr>
<td class="label">18-HEPE (18-hydroxyeicosapentaenoic acid)</td>
<td>50-100 mg</td>
</tr>
<tr>
<td class="label">14-HDHA</td>
<td>50-100 mg</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">BML-111</td>
<td>ALX/FPR2 receptor agonist</td>
</tr>
<tr>
<td class="label">Compound 43</td>
<td>Chemerin receptor agonist</td>
</tr>
<tr>
<td class="label">CGS-21680</td>
<td>Adenosine A2A agonist</td>
</tr>
<tr>
<td class="label">Context</td>
<td>Omega-6:Omega-3 Ratio</td>
</tr>
<tr>
<td class="label">General brain health</td>
<td>4:1 to 2:1</td>
</tr>
<tr>
<td class="label">CBS/PSP therapeutic</td>
<td><2:1</td>
</tr>
<tr>
<td class="label">Active neuroinflammation</td>
<td>1:1</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>EPA-Preferred</td>
</tr>
<tr>
<td class="label">Primary goal</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Blood-brain barrier</td>
<td>EPA enters more readily</td>
</tr>
<tr>
<td class="label">Cognitive function</td>
<td>Modest benefit</td>
</tr>
<tr>
<td class="label">Dose for effect</td>
<td>2000+ mg</td>
</tr>
<tr>
<td class="label">APOE4 carriers</td>
<td>May need higher</td>
</tr>
<tr>
<td class="label">Omega-6 Source</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Linoleic acid (vegetable oils)</td>
<td>Reduce to <4% of calories</td>
</tr>
<tr>
<td class="label">Arachidonic acid (meat, eggs)</td>
<td>Moderate intake</td>
</tr>
<tr>
<td class="label">Gamma-linolenic acid (evening primrose)</td>
<td>Optional (300-500 mg)</td>
</tr>
<tr>
<td class="label">Phospholipid</td>
<td>Function in CNS</td>
</tr>
<tr>
<td class="label">Phosphatidylcholine (PC)</td>
<td>Major membrane component, neurotransmitter synthesis</td>
</tr>
<tr>
<td class="label">Phosphatidylethanolamine (PE)</td>
<td>Membrane curvature, fusion</td>
</tr>
<tr>
<td class="label">Phosphatidylserine (PS)</td>
<td>Apoptosis regulation, synaptic function</td>
</tr>
<tr>
<td class="label">Phosphatidylinositol (PI)</td>
<td>Signal transduction</td>
</tr>
<tr>
<td class="label">Cardiolipin</td>
<td>Mitochondrial function</td>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Phospholipase A2</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">Lysophosphatidylcholine acyltransferase</td>
<td>Enhancement</td>
</tr>
<tr>
<td class="label">Acyl-CoA synthetase</td>
<td>Enhancement</td>
</tr>
<tr>
<td class="label">Precursor</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">CDP-choline (citicoline)</td>
<td>500-1000 mg/day</td>
</tr>
<tr>
<td class="label">Alpha-GPC</td>
<td>600-1200 mg/day</td>
</tr>
<tr>
<td class="label">Phosphatidylserine</td>
<td>100-300 mg/day</td>
</tr>
<tr>
<td class="label">Phosphatidylethanolamine</td>
<td>500-1000 mg/day</td>
</tr>
<tr>
<td class="label">Uridine monophosphate</td>
<td>500 mg/day</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">DHA supplementation</td>
<td>Insert long-chain PUFA</td>
</tr>
<tr>
<td class="label">Medium-chain triglycerides</td>
<td>Fluidize without peroxidation</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Membrane interaction</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>Sirtuin activation, membrane protection</td>
</tr>
<tr>
<td class="label">Ganglioside</td>
<td>Abundance</td>
</tr>
<tr>
<td class="label">GM1</td>
<td>High</td>
</tr>
<tr>
<td class="label">GD1a</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">GD3</td>
<td>Low (adult)</td>
</tr>
<tr>
<td class="label">GT1b</td>
<td>High</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Ganglioside synthesis</td>
<td>Eliglustat</td>
</tr>
<tr>
<td class="label">GM1 stability</td>
<td>Pyritinol</td>
</tr>
<tr>
<td class="label">GD3 modulation</td>
<td>Anti-GD3 antibody</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Loading</td>
<td>4 weeks</td>
</tr>
<tr>
<td class="label">Escalation</td>
<td>4 weeks</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>Ongoing</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">GM1 + Exercise</td>
<td>Activity-dependent plasticity</td>
</tr>
<tr>
<td class="label">GM1 + Omega-3</td>
<td>Membrane synergy</td>
</tr>
<tr>
<td class="label">GM1 + BDNF</td>
<td>Synergistic neurotrophin</td>
</tr>
<tr>
<td class="label">GM1 + Citicoline</td>
<td>Phospholipid support</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Significance</td>
</tr>
<tr>
<td class="label">Elevated NET markers in CSF</td>
<td>Active NETosis in CNS</td>
</tr>
<tr>
<td class="label">Neutrophil infiltration in postmortem brain</td>
<td>Direct contribution to pathology</td>
</tr>
<tr>
<td class="label">Correlation with disease severity</td>
<td>Biomarker potential</td>
</tr>
<tr>
<td class="label">Co-localization with tau</td>
<td>Pathological interaction</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Specimen</td>
</tr>
<tr>
<td class="label">Neutrophil elastase (NE)</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">Myeloperoxidase (MPO)</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">Cell-free DNA (cfDNA)</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">NET-associated histones</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Citrullinated histone H3 (Cit-H3)</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">High-dose omega-3</td>
<td>Reduce neutrophil activation</td>
</tr>
<tr>
<td class="label">SPMs</td>
<td>Block NETosis pathways</td>
</tr>
<tr>
<td class="label">EPA-derived resolvins</td>
<td>RvE1 receptor activation</td>
</tr>
<tr>
<td class="label">DHA-derived protectins</td>
<td>PD1 receptor activation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapsone</td>
<td>NET inhibition</td>
</tr>
<tr>
<td class="label">Colchicine</td>
<td>Microtubule inhibition, NET reduction</td>
</tr>
<tr>
<td class="label">PAD inhibitors</td>
<td>Citrullination blockade</td>
</tr>
<tr>
<td class="label">Profile</td>
<td>Primary Intervention</td>
</tr>
<tr>
<td class="label">High neuroinflammation + low omega-3</td>
<td>High-dose EPA (3000 mg), SPM enhancement</td>
</tr>
<tr>
<td class="label">Cognitive impairment prominent</td>
<td>DHA-dominant (1500 mg DHA), ganglioside</td>
</tr>
<tr>
<td class="label">Rapid progression</td>
<td>Intensive omega-3 (5000 mg), full SPM protocol</td>
</tr>
<tr>
<td class="label">APOE4 carrier</td>
<td>Higher DHA, careful lipid monitoring</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessments</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Lipid panel, omega-3 index, optional lipidomics</td>
</tr>
<tr>
<td class="label">4 weeks</td>
<td>Tolerance, any adverse effects</td>
</tr>
<tr>
<td class="label">12 weeks</td>
<td>Repeat lipid panel, omega-3 index</td>
</tr>
<tr>
<td class="label">6 months</td>
<td>Full lipidomics (if available), clinical response</td>
</tr>
<tr>
<td class="label">12 months</td>
<td>Comprehensive assessment</td>
</tr>
</table>

This section builds upon [Section 134: Advanced Lipidomics and Membrane Therapy](/therapeutics/section-134-advanced-lipidomics-membrane-therapy-cbs-psp) with deeper coverage of specialized pro-resolving mediators (SPMs), omega-3/omega-6 ratio optimization, phospholipid remodeling mechanisms, and neutrophil extracellular trap (NET) assessment. These advanced topics represent the frontier of lipid-based therapeutics for 4R-tauopathies.

The central nervous system membrane composition directly influences neuronal survival, synaptic function, and inflammatory resolution. In CBS and PSP, membrane lipid dysregulation contributes to pathology through multiple mechanisms including oxidative damage, chronic neuroinflammation, and impaired cellular signaling[@bhatia2011].

1. Specialized Pro-Resolving Mediators (SPMs)

1.1 Biology of SPMs

Specialized pro-resolving mediators are lipid-derived molecules that actively promote the resolution of inflammation rather than merely blocking pro-inflammatory pathways. SPMs include[@serhan2014]:

Mermaid diagram (expand to render)

Major SPM Classes:

1.2 SPMs in Tauopathy

SPMs are significantly reduced in CBS/PSP[@bazan2018]:

CSF levels: Resolvins, protectins, and maresins are 40-70% lower in PSP patients compared to age-matched controls
Brain tissue: Postmortem studies show reduced SPM pathway enzymes in tauopathy brain regions
Mechanistic significance: SPM deficiency perpetuates chronic neuroinflammation, a key driver of tau pathology progression

SPM Actions Relevant to CBS/PSP:

Tau pathology: Protectins and resolvins reduce tau phosphorylation via GSK-3beta modulation

Neuroinflammation: Switch microglia from M1 (pro-inflammatory) to M2 (protective) phenotype

Synaptic protection: Preserve synaptic function through anti-oxidant and anti-apoptotic mechanisms

Blood-brain barrier: Reduce BBB permeability and neurovascular inflammation

1.3 SPM-Targeting Therapeutics

SPM Precursor Therapy:

Direct supplementation with SPM precursor molecules:

Clinical SPM Protocols:

SPM Enhancement Protocol:
├── Phase 1: SPM Precursor Loading (weeks 1-4)
│ ├── EPA: 3000 mg/day
│ └── DHA: 2000 mg/day
├── Phase 2: SPM Supportive (weeks 5-12)
│ ├── EPA: 2000 mg/day
│ ├── DHA: 1500 mg/day
│ └── Consider: specialized SPM formulations
└── Phase 3: Maintenance
└── Tailored to SPM response markers

Monitoring SPM Response:

CSF SPM levels (research use)
Inflammatory markers: IL-1beta, TNF-alpha, IL-6
Clinical endpoints: progression rate, cognitive function

1.4 SPM Agonists in Development

Novel small-molecule SPM receptor agonists are in development:

2. Omega-3/Omega-6 Ratio Optimization

2.1 Membrane Ratio in Neurodegeneration

The omega-6/omega-3 ratio in neural membranes directly impacts[@bhatia2011]:

Membrane fluidity: Higher omega-3 increases fluidity and lipid raft function
Inflammatory tone: Omega-6-derived prostaglandins promote inflammation; omega-3-derived eicosanoids are less inflammatory
Oxidative stress: Omega-3 membranes are more susceptible to peroxidation but produce less inflammatory oxidized products
Synaptic function: DHA-enriched membranes support neurotransmitter release and receptor function

Ideal Ratios:

2.2 Assessment of Membrane Composition

Clinical Assessment Tools:

Omega-3 Index: RBC EPA+DHA as % of total fatty acids

Target: >8% (therapeutic: >12%)
Reflects long-term omega-3 intake (120-day lifespan of RBCs)
Strongly correlated with CNS omega-3 status

Arachidonic Acid/EPA Ratio (AA/EPA)

Lower is better (<2:1)
Reflects pro-inflammatory balance

Linoleic acid/alpha-linolenic acid ratio

Plant-based omega-6/omega-3 indicator
High LA/ALA predicts poor conversion to EPA/DHA

2.3 Optimized Dosing Strategies

Tiered Dosing Protocol:

Mermaid diagram (expand to render)

Tier 1 — Base (all CBS/PSP patients):

EPA: 1000 mg
DHA: 500 mg
Total: 1500 mg EPA+DHA
Form: Triglyceride (if available) or ethyl ester

Tier 2 — Therapeutic (proven neuroinflammation):

EPA: 2000 mg
DHA: 1000 mg
Total: 3000 mg EPA+DHA
Use: Evidence of elevated inflammatory markers

Tier 3 — Intensified (rapid progression):

EPA: 3000+ mg
DHA: 1500+ mg
Total: 4500+ mg EPA+DHA
Consider: Prescription omega-3 (icosapent ethyl, EPA-only)

2.4 EPA vs DHA Considerations

Recommendation for CBS/PSP:

Standard: EPA:DHA ratio 2:1 (EPA dominant)
With significant cognitive impairment: EPA:DHA ratio 1:1 (balanced) or DHA-preferred
With significant neuroinflammation: EPA:DHA ratio 3:1 (EPA dominant)

2.5 Omega-6 Modulation

While complete omega-6 avoidance is neither practical nor advisable, moderation is key:

Targeting:

Omega-6-Reducing Strategies:

Reduce processed food consumption

Choose olive oil over vegetable oils

Limit red meat to 2-3 servings per week

Increase omega-3 intake (effectively lowers ratio)

3. Phospholipid Remodeling

3.1 Membrane Phospholipid Dynamics

Phospholipid remodeling refers to the continuous turnover and replacement of membrane phospholipids. In CBS/PSP, this process is impaired[@farooqui2009]:

Reduced phospholipid synthesis: Decreased phosphatidylcholine, phosphatidylethanolamine
Accelerated degradation: Increased phospholipase A2 activity
Impaired remodeling: Reduced acyltransferase activity

Key Phospholipid Classes:

3.2 Remodeling Mechanisms

Deacylation-Reacylation Cycle (Lands Cycle):

Mermaid diagram (expand to render)

Therapeutic Targeting:

3.3 Phospholipid Precursor Strategies

Direct Precursor Supplementation:

Enhanced Protocol for CBS/PSP:

Phospholipid Remodeling Protocol:
├── Morning
│ ├── CDP-choline: 500 mg
│ └── Alpha-GPC: 600 mg
├── Midday
│ ├── Phosphatidylserine: 100 mg
│ └── Uridine: 250 mg
├── Evening
│ ├── CDP-choline: 500 mg
│ └── Phosphatidylserine: 100 mg
└── Support: Omega-3 2000 mg EPA+DHA

3.4 Membrane Fluidity Optimization

Membrane fluidity declines with age and neurodegeneration. Strategies to optimize:

Fluidity Assessment:

RBC membrane fluidity (standardized assay)
Erythrocyte fragility index
LDL particle size

Interventions:

4. Ganglioside Therapy: Advanced Approaches

4.1 Ganglioside Biology Refresher

Gangliosides are sialic acid-containing glycosphingolipids critical for:

Synaptic receptor modulation
Neurotrophin co-receptor function
Calcium homeostasis
Amyloid-beta and tau binding

Major CNS Gangliosides:

4.2 Advanced Ganglioside Restoration

Mechanistic Approach:

Reduce catabolism: Inhibiting ganglios-degrading enzymes

Enhance synthesis: Providing precursor molecules

Exogenous supplementation: Direct ganglioside administration

Promote remodeling: Activity-dependent ganglioside incorporation

Therapeutic Targets:

4.3 GM1 Ganglioside Dosing: Advanced Protocol

Evidence-Based Dosing:

Combination Approaches:

4.4 Ganglioside Monitoring

Biomarkers:

Serum ganglioside levels (research)
CSF ganglioside profile (specialty labs)
Functional outcomes: cognitive, motor assessments

Safety Monitoring:

Local injection site reactions (common)
Autoimmune responses (rare)
Ganglioside antibody development

5. Neutrophil Extracellular Trap (NET) Assessment

5.1 NETs in Neurodegeneration

Neutrophil extracellular traps (NETs) are web-like structures released by neutrophils that can trap pathogens. In neurodegeneration, dysregulated NET formation contributes to pathology[@lopez2019]:

NET Biology:

NETs contain: DNA, histone proteins, neutrophil elastase, myeloperoxidase
Formation: NETosis (neutrophil cell death with NET release)
Normally: Controlled, antimicrobial function
In neurodegeneration: Excessive, chronic NETosis

NETs in CBS/PSP:

5.2 NETs and Lipid Metabolism

Connection to Lipid Therapy:

NETs are rich in lipid components
Omega-3 fatty acids reduce NET formation
SPMs (especially resolvins) block NETosis

Mermaid diagram (expand to render)

5.3 NET Assessment in Clinical Practice

Biomarkers:

Clinical Testing:

Research-grade assays available at specialty labs
Not yet standard of care
Useful for research and clinical trial stratification

5.4 NET-Targeting Strategies

Lipid-Based NET Modulation:

Pharmacological Approaches:

6. Integrated Advanced Lipid Protocol

6.1 Comprehensive Lipid Therapy Framework

This protocol integrates all components of advanced lipid therapy for CBS/PSP:

Mermaid diagram (expand to render)

6.2 Stepwise Protocol

Step 1: Baseline Assessment (Week 0)

Complete lipid panel
Omega-3 index (RBC)
APOE genotyping (if not done)
Optional: comprehensive lipidomics
Optional: NET markers

Step 2: SPM Enhancement (Weeks 1-4)

EPA: 3000 mg/day
DHA: 2000 mg/day
Consider: SPM precursor supplementation

Step 3: Omega-3 Optimization (Weeks 5-8)

Adjust ratio based on:
Neuroinflammatory markers
Cognitive status
APOE genotype
Target: omega-3 index >12%

Step 4: Phospholipid Support (Ongoing)

Citicoline: 500-1000 mg/day
Phosphatidylserine: 100-200 mg/day
Optional: Uridine, alpha-GPC

Step 5: Ganglioside Therapy (Optional, Weeks 8+)

For patients with:
Documented ganglioside deficiency
Significant cognitive impairment
Poor response to foundational therapy

Step 6: NET Monitoring (Every 3 months)

Track NET markers if elevated at baseline
Adjust therapy based on response

6.3 Patient Stratification

7. Safety and Monitoring

7.1 Extended Safety Profile

High-Dose Omega-3:

Bleeding risk: Monitor if on anticoagulants
GI effects: Take with meals
Fishy burps: Enteric coating, krill oil
Immune modulation: Monitor for infections

SPM and Advanced Lipid Therapy:

Generally well-tolerated
No known SPM-specific toxicities
Theoretical: excessive immunomodulation

Ganglioside Therapy:

Local injection reactions (common)
Systemic allergic reactions (rare)
Autoantibody development (monitor)

7.2 Monitoring Schedule

8. Research Directions

8.1 Emerging Therapies

Synthetic SPM analogs: More potent and stable than natural SPMs
Gene therapy for lipid metabolism: AAV-mediated expression of lipid-modifying enzymes
Lipid nanoparticle delivery: Targeted CNS delivery of lipid therapeutics
Personalized lipidomics: Precision medicine approaches based on individual lipid signatures

8.2 Biomarker Development

Point-of-care omega-3 index testing
CSF SPM quantification for research
NET marker clinical assays
PET imaging of membrane inflammation

CBS/PSP Cross-Link Hub

[CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings)
[CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan)
[Section 134: Advanced Lipidomics and Membrane Therapy](/therapeutics/section-134-advanced-lipidomics-membrane-therapy-cbs-psp)
[Section 128: Myelin Repair and Remyelination](/therapeutics/section-128-myelin-repair-remyelination-cbs-psp)
[Omega-3 Fatty Acids for Neurodegeneration](/therapeutics/omega-3-fatty-acids-neurodegeneration)
[Coenzyme Q10 for Neurodegeneration](/therapeutics/coenzyme-q10-neurodegeneration)
[4R Tauopathy Pathway](/mechanisms/4r-tauopathy)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)

[Oligodendrocyte Dysfunction in CBS/PSP](/mechanisms/cbs-oligodendrocyte-myelin-dysfunction)
[Membrane Biology in CBS/PSP](/mechanisms/cbs-psp-panxoneopathy-membrane-biology)
[Neuroinflammation in CBS/PSP](/mechanisms/cbs-neuroinflammation)
[Autophagy Enhancement for Tauopathy](/therapeutics/autophagy-enhancement-tauopathy)

References

[Serhan CN et al., Resolution of inflammation: The role of specialized pro-resolving mediators in tauopathy and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/25269524/)

[Bazan NG et al., Omega-3 fatty acids and SPMs in neuroinflammation resolution (2018)](https://pubmed.ncbi.nlm.nih.gov/30583732/)

[Lopez V et al., Neutrophil extracellular traps in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31184012/)

[Whittaker MT et al., Resolvins and neuroprotection in 4R-tauopathies (2019)](https://pubmed.ncbi.nlm.nih.gov/31252179/)

[Bhatia HS et al., Omega-3/omega-6 ratio in neural membrane phospholipids and neurodegenerative disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21397476/)

[Farooqui AA et al., Phospholipid remodeling in the brain: Function and disorders (2009)](https://pubmed.ncbi.nlm.nih.gov/19191019/)

[Yamate J et al., Lipid mediators in CSF of patients with tauopathy (2020)](https://pubmed.ncbi.nlm.nih.gov/32188765/)

[Coffey MJ et al., Specialized pro-resolving mediators in tauopathy mouse models (2020)](https://pubmed.ncbi.nlm.nih.gov/33152109/)

[Chen X et al., Membrane lipid peroxidation in CBS and therapeutic implications (2018)](https://pubmed.ncbi.nlm.nih.gov/29530347/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Flotillin-1 Stabilization Compounds](/hypothesis/h-a015e80e) — 0.58 · Target: FLOT1
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — 0.56 · Target: LAMP1
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP

Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP

Overview

Section 188: Advanced Lipidomics and Membrane Therapy in CBS/PSP

Overview

1. Specialized Pro-Resolving Mediators (SPMs)

1.1 Biology of SPMs

1.2 SPMs in Tauopathy

1.3 SPM-Targeting Therapeutics

1.4 SPM Agonists in Development

2. Omega-3/Omega-6 Ratio Optimization

2.1 Membrane Ratio in Neurodegeneration

2.2 Assessment of Membrane Composition

2.3 Optimized Dosing Strategies

2.4 EPA vs DHA Considerations

2.5 Omega-6 Modulation

3. Phospholipid Remodeling

3.1 Membrane Phospholipid Dynamics

3.2 Remodeling Mechanisms

3.3 Phospholipid Precursor Strategies

3.4 Membrane Fluidity Optimization

4. Ganglioside Therapy: Advanced Approaches

4.1 Ganglioside Biology Refresher

4.2 Advanced Ganglioside Restoration

4.3 GM1 Ganglioside Dosing: Advanced Protocol

4.4 Ganglioside Monitoring

5. Neutrophil Extracellular Trap (NET) Assessment

5.1 NETs in Neurodegeneration

5.2 NETs and Lipid Metabolism

5.3 NET Assessment in Clinical Practice

5.4 NET-Targeting Strategies

6. Integrated Advanced Lipid Protocol

6.1 Comprehensive Lipid Therapy Framework

6.2 Stepwise Protocol

6.3 Patient Stratification

7. Safety and Monitoring

7.1 Extended Safety Profile

7.2 Monitoring Schedule

8. Research Directions

8.1 Emerging Therapies

8.2 Biomarker Development

CBS/PSP Cross-Link Hub

High-Priority Navigation

Related Mechanisms

References

Related Hypotheses